Product Description: Bemcentinib (R428) GMP is an orally active and selective inhibitor of Axl with an IC50 of 14 nM[1][2].
Applications: Cancer-Kinase/protease
Formula: C30H34N8
References: [1]Lijnen HR, et al. Growth arrest-specific protein 6 receptor antagonism impairs adipocyte differentiation and adipose tissue development in mice. J Pharmacol Exp Ther. 2011 May;337(2):457-64./[2]Sensi M, et al. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol. 2011 Dec;131(12):2448-57./[3]Holland SJ, et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 2010 Feb 15;70(4):1544-54.
CAS Number: 1037624-75-1
Molecular Weight: 506.64
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: TAM Receptor
English
Deutsch
